InvestLog
KTTA Pasithea Therapeutics Corp. logo

KTTA Pasithea Therapeutics Corp.

Healthcare
$0.70-2.94%ClosedMarket Cap: $5.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.00

P/S

0.00

EV/EBITDA

2355.43

DCF Value

$7.85

FCF Yield

-325.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-0.1%

ROA

-0.0%

ROIC

-0.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-2.9M$—
Q4 null$0.00$-10.1M$—
FY null$0.00$-20.4M$—
Q3 null$0.00$-3.0M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$3.00

Target (Median)

$3.00

Target Range

$3.00 - $3.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-04-20

Trading Activity

Insider Trades

View All
STEINMAN LAWRENCEdirector
SellTue May 05
Schneiderman Daniel Hofficer: Chief Financial Officer
SellTue May 05
Novak Alfred Jdirector
SellTue May 05
Marques Tiagodirector, officer: Chief Executive Officer
SellTue May 05
Leahy Emerdirector
SellTue May 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

0.22

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Peers

AIM logoAIMCYCN logoCYCNIBO logoIBOKALA logoKALANBY logoNBYPLRZ logoPLRZQNRX logoQNRXTCRT logoTCRTVIVS logoVIVSVYNE logoVYNE